Access cutting-edge cancer treatment through this clinical trial at a research site in Skokie. Study-provided care at no cost to qualified participants.
Access cancer specialists in Skokie at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cancer treatment provided free
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu
Sponsor: Eisai Inc.
Check if you qualify for this cancer clinical trial in Skokie, IL
If you're searching for cancer treatment options in Skokie, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Skokie research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.